I’ve just published a new book, by Michael L. Salgaller, PhD. In Biotechnology Entrepreneurship: From Science to Solutions Michael combines the voices of a diverse set of industry insiders with extensive experience in biotechnology commercialization to prepares nascent founders, managers, investors, and other biotechnology company stakeholders to position themselves and their companies for commercial success.
Topics covered include:
- Why Start a Biotechnology Company?
- Company Formation and Organization
- Building Your Team
- Intellectual Property Protection Strategy
- Financing Your Company
- Partnering With Industry
- Licensing and Technology Transfer
- Regulatory Affairs
- Roadmap to Reimbursement and Access
- Working Toward a Successful Exit
Full details on the book are available on Logos Press’ website, and the book is available at Barnes and Noble, Amazon.com, and elsewhere.
I will be moderating a panel on the roles of biotechnology in development at the upcoming A Better World by Design conference at Brown University. The theme of the panel will be the promise and challenges of implementing biotechnology advances for public benefit, with a focus on topics such as disease prevention, agricultural improvements, and political hurdles.
The panel will be on October 1st at Brown University. For more details, see the A Better World by Design website.
Kraig Biocraft Laboratories, Inc. (OTC.BB:KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.
“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”
In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month. Earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.
For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com
I’ve posted a new Drug Patent Challenge Report at thinkPharm.com.
This new report complements the Drug Patent Inventor Report and Orphan Drug Report and profiles the companies that successfully challenged pharmaceutical drug patents.
The Drug Patent Challenge Report includes:
- A list of the companies with the most successful patent challenges
- A list of all the drugs for which each firm successfully challenged a patent
- A list of all the companies that have received FDA approval for each listed drug
- More than 60 companies profiled
- More than 80 drugs profiled
A preview of the report is also available.
Do you need any other pharmaceutical drug and patent reports? Let me know.